Observational studyUnited European gastroenterology journal2020
The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.
Observational study in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Interventions for maintenance of surgically induced remission in Crohn's disease: a systematic review and network meta-analysis.BMJ open gastroenterology · 2025Pooled it
- Practices and perceptions of 5-aminosalicylic acid use in Crohn's disease: a nationwide survey of physicians in Korea by KASID Guidelines Taskforce Team.Intestinal research · 2025Article
- Clinical and Genetic Characteristics of Pediatric Patients with Inflammatory Bowel Disease Transitioning to Adult Medicine: A Single-Center Ten-Year Experience.Journal of clinical medicine · 2025Article
- Prospective Evaluation of the Prediction Score for a Mild Course of Crohn's Disease (PreMiCC) in Newly Diagnosed Patients With Crohn's Disease: The PROGNOS Study.Inflammatory bowel diseases · 2025Observational
- Mesalazine-Induced Acute Pancreatitis in Inflammatory Bowel Disease Patients: A Systematic Review.Therapeutics and clinical risk management · 2025Review
- New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases.Therapeutic advances in gastroenterology · 2024Article
- Crohn's disease and clinical management today: How it does?World journal of methodology · 2023Review
- Reclassification of Inflammatory Bowel Disease Type Unclassified by Small Bowel Capsule Endoscopy.Medicina (Kaunas, Lithuania) · 2023Article
- Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists.Journal of clinical medicine · 2023Article
- Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis.Therapeutic advances in gastroenterology · 2023Review
- Genital warts and inflammatory bowel diseases: Danish real-world evidence to assess patient-relevant outcomes.United European gastroenterology journal · 2022Article
- Evaluation of Anti-Inflammatory and Antioxidant Effectsof Chrysanthemum Stem and Leaf Extract on Zebrafish Inflammatory Bowel Disease Model.Molecules (Basel, Switzerland) · 2022Article
- UEGWeek: The modern School of Athens.United European gastroenterology journal · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 22 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.
aimsThe aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.
methodsIn a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.
resultsOverall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).
conclusionIn this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.